Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial
Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer.To determine whether fluorouracil or gemcitabine is su...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 8, 2010
|
| In: |
The journal of the American Medical Association
Year: 2010, Volume: 304, Issue: 10, Pages: 1073-1081 |
| ISSN: | 1538-3598 |
| DOI: | 10.1001/jama.2010.1275 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jama.2010.1275 |
| Author Notes: | John P. Neoptolemos, MD, Deborah D. Stocken, PhD, Claudio Bassi, MD, Paula Ghaneh, MD, David Cunningham, MD, David Goldstein, MD, Robert Padbury, MD, Malcolm J. Moore, MD, Steven Gallinger, MD, Christophe Mariette, MD, Moritz N. Wente, MD, Jakob R. Izbicki, MD, Helmut Friess, MD, Markus M. Lerch, MD, Christos Dervenis, MD, Attila Oláh, MD, Giovanni Butturini, MD, Ryuichiro Doi, MD, Pehr A. Lind, MD, David Smith, MD, Juan W. Valle, MD, Daniel H. Palmer, MD, John A. Buckels, MD, Joyce Thompson, MD, Colin J. McKay, MD, Charlotte L. Rawcliffe, MSc, Markus W. Büchler, MD, for the European Study Group for Pancreatic Cancer |